Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sparfloxacin
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sparfloxacin is a synthetic fluoroquinolone antibiotic used to treat bacterial respiratory infections such as bronchitis and pneumonia, as well as sinusitis. It acts by inhibiting bacterial DNA gyrase, an essential enzyme for DNA replication, repair, deactivation, and transcription in bacteria. This inhibition disrupts bacterial cell division and leads to cell death. Sparfloxacin exhibits broad-spectrum activity against both gram-positive and gram-negative organisms. It has been withdrawn from the U.S. market due to safety concerns but may still be available elsewhere[1][2][3][5][6].
- Brand names
- ZagamZagam Respipac
- Other names
- sparfloxacin
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on sparfloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sparfloxacin.